Generic placeholder image

Current HIV Research

Author(s): Tennison Onoriode Digban*, Benson Chucks Iweriebor, Larry Chikwelu Obi, Uchechuwku Nwodo and Anthony Ifeanyi Okoh

DOI: 10.2174/1570162X17666191004093433

DownloadDownload PDF Flyer Cite As
Molecular Genetics and the Incidence of Transmitted Drug Resistance Among Pre-Treatment HIV-1 Infected Patients in the Eastern Cape, South Africa

Page: [335 - 342] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Transmitted drug resistance (TDR) remains a significant threat to Human immunodeficiency virus (HIV) infected patients that are not exposed to antiretroviral treatment. Although, combined antiretroviral therapy (cART) has reduced deaths among infected individuals, emergence of drug resistance is gradually on rise.

Objective: To determine the drug resistance mutations and subtypes of HIV-1 among pre-treatment patients in the Eastern Cape of South Africa.

Methods: Viral RNA was extracted from blood samples of 70 pre-treatment HIV-1 patients while partial pol gene fragment amplification was achieved with specific primers by RT-PCR followed by nested PCR and positive amplicons were sequenced utilizing ABI Prism 316 genetic sequencer. Drug resistance mutations (DRMs) analysis was performed by submitting the generated sequences to Stanford HIV drug resistance database.

Results: Viral DNA was successful for 66 (94.3%) samples of which 52 edited sequences were obtained from the protease and 44 reverse transcriptase sequences were also fully edited. Four major protease inhibitor (PI) related mutations (I54V, V82A/L, L76V and L90M) were observed in seven patients while several other minor and accessory PIs were also identified. A total of 11(25.0%) patients had NRTIs related mutations while NNRTIs were observed among 14(31.8%) patients. K103N/S, V106M and M184V were the most common mutations identified among the viral sequences. Phylogenetic analysis of the partial pol gene indicated all sequences clustered with subtype C.

Conclusion: This study indicates that HIV-1 subtype C still predominates and responsible for driving the epidemic in the Eastern Cape of South Africa with slow rise in the occurrence of transmitted drug resistance.

Keywords: HIV-1, Transmitted drug resistance, antiretroviral therapy, NNRTIs, NRTIs, PIs.

Graphical Abstract

[1]
Peeters M, Aghokeng AF, Delaporte E. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect 2010; 16(10): 1525-31.
[http://dx.doi.org/10.1111/j.1469-0691.2010.03300.x] [PMID: 20649800]
[2]
Vallari A, Holzmayer V, Harris B, et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 2011; 85(3): 1403-7.
[http://dx.doi.org/10.1128/JVI.02005-10] [PMID: 21084486]
[3]
Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15(8): 871-2.
[http://dx.doi.org/10.1038/nm.2016] [PMID: 19648927]
[4]
Rubio AE, Abraha A, Carpenter CA, et al. Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina. PLoS One 2014; 9(4)e92084
[http://dx.doi.org/10.1371/journal.pone.0092084] [PMID: 24727861]
[5]
Bártolo I, Taveira N. HIV-1 diversity and its implications in diagnosis, transmission, disease progression, and antiretroviral therapy Genetic Diversity in Microorganisms. Intech Open 2012.
[6]
Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science 2000; 288(5463): 55-6.
[http://dx.doi.org/10.1126/science.288.5463.55d] [PMID: 10766634]
[7]
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization 2016.
[8]
UNAIDS Fast-Track, Ending the AIDS Epidemic by 2030 http://www.unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014 Accessed May 24, 2017.
[9]
Cornell M, Johnson LF, Wood R, et al. International epidemiology databases to evaluate AIDS-Southern Africa collaboration. twelve-year mortality in adults initiating antiretroviral therapy in South Africa. J Int AIDS Soc 2017; 20(1): 21902.
[http://dx.doi.org/10.7448/IAS.20.1.21902] [PMID: 28953328]
[10]
Wilkinson E, Holzmayer V, Jacobs GB, et al. Sequencing and phylogenetic analysis of near full-length HIV-1 subtypes A, B, G and unique recombinant AC and AD viral strains identified in South Africa. AIDS Res Hum Retroviruses 2015; 31(4): 412-20.
[http://dx.doi.org/10.1089/aid.2014.0230] [PMID: 25492033]
[11]
Jacobs GB, Wilkinson E, Isaacs S, et al. HIV-1 subtypes B and C unique recombinant forms (URFs) and transmitted drug resistance identified in the Western Cape Province, South Africa. PLoS One 2014; 9(6)e90845
[http://dx.doi.org/10.1371/journal.pone.0090845] [PMID: 24609015]
[12]
Ketseoglou I, Lukhwareni A, Steegen K, Carmona S, Stevens WS, Papathanasopoulos MA. Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa. AIDS Res Hum Retroviruses 2014; 30(3): 289-93.
[http://dx.doi.org/10.1089/aid.2013.0267] [PMID: 24224886]
[13]
Bessong PO, Iweriebor B. A putative HIV-1 subtype C/CRF11_cpx unique recombinant from South Africa. Springerplus 2016; 5(1): 285.
[http://dx.doi.org/10.1186/s40064-016-1924-z] [PMID: 27047711]
[14]
Musyoki AM, Rakgole JN, Selabe G, Mphahlele J. Identification and genetic characterization of unique HIV-1 A1/C recombinant strain in South Africa. AIDS Res Hum Retroviruses 2015; 31(3): 347-52.
[http://dx.doi.org/10.1089/aid.2014.0212] [PMID: 25517728]
[15]
Iweriebor BC, Bessong PO, Mavhandu LG, et al. Genetic analysis of the near full-length genome of an HIV type 1 A1/C unique recombinant form from northern South Africa. AIDS Res Hum Retroviruses 2011; 27(8): 911-5.
[http://dx.doi.org/10.1089/aid.2010.0286] [PMID: 21087143]
[16]
Bredell H, Hunt G, Casteling A, et al. HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res Hum Retroviruses 2002; 18(9): 681-3.
[http://dx.doi.org/10.1089/088922202760019400] [PMID: 12079566]
[17]
Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med 2017; 18(1): 776.
[http://dx.doi.org/10.4102/sajhivmed.v18i1.776] [PMID: 29568644]
[18]
Mendoza Y, Castillo Mewa J, Martínez AA, et al. HIV-1 antiretroviral drug resistance mutations in treatment naive and experienced Panamanian subjects: impact on national use of EFV-based schemes. PLoS One 2016; 11(4)e0154317
[http://dx.doi.org/10.1371/journal.pone.0154317] [PMID: 27119150]
[19]
Lihana RW, Ssemwanga D, Abimiku A, Ndembi N. Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev 2012; 14(2): 83-100.
[PMID: 22627605]
[20]
Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14(1): 17-27.
[PMID: 22297501]
[21]
Nachega BJ, Marconi CV, van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts Infectious Disorders-Drug Targets (Formerly Current Drug Targets- Infectious Disorders) 2011; 11(2): 167-74.
[http://dx.doi.org/10.2174/187152611795589663]
[22]
Drescher SM, von Wyl V, Yang WL, et al. Swiss HIV Cohort Study. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2014; 58(2): 285-94.
[http://dx.doi.org/10.1093/cid/cit694] [PMID: 24145874]
[23]
Gatanaga H, Ibe S, Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007; 75(1): 75-82.
[http://dx.doi.org/10.1016/j.antiviral.2006.11.012] [PMID: 17194486]
[24]
Iweriebor BC, Mavhandu LG, Masebe T, et al. Molecular epidemiology of HIV in two highly endemic areas of northeastern South Africa. Arch Virol 2012; 157(3): 455-65.
[http://dx.doi.org/10.1007/s00705-011-1180-z] [PMID: 22189822]
[25]
van Zyl GU, Cotton MF, Claassen M, Abrahams C, Preiser W. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa. Pediatr Infect Dis J 2010; 29(4): 370-1.
[PMID: 19935449]
[26]
Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV-1 clade C resistance genotypes in naïve patients and after first virological failure in a large community ART programme. Antivir Ther 2009; 14(4): 523.
[PMID: 19578237]
[27]
Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther (Lond) 2008; 13(Suppl. 2): 101-7.
[PMID: 18575198]
[28]
Bessong PO, Larry Obi C, Cilliers T, et al. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses 2005; 21(1): 103-9.
[http://dx.doi.org/10.1089/aid.2005.21.103] [PMID: 15665650]
[29]
Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther (Lond) 2008; 13(Suppl. 2): 25-36.
[PMID: 18575189]
[30]
Vahabpour R, Bokharaei-Salim F, Kalantari S, et al. HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Arch Virol 2017; 162(6): 1477-85.
[http://dx.doi.org/10.1007/s00705-017-3228-1] [PMID: 28181034]
[31]
Li H, Chang S, Han Y, et al. The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004. BMC Infect Dis 2016; 16(1): 605.
[http://dx.doi.org/10.1186/s12879-016-1928-x] [PMID: 27782811]
[32]
Kotaki T, Khairunisa SQ, Witaningrum AM, et al. HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia. AIDS Res Ther 2015; 12(1): 5.
[http://dx.doi.org/10.1186/s12981-015-0046-y] [PMID: 28561075]
[33]
Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 2009; 13(5): 552-9.
[http://dx.doi.org/10.1016/j.ijid.2008.10.008] [PMID: 19136289]
[34]
Marconi VC, Sunpath H, Lu Z, et al. South Africa resistance cohort study team. prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46(10): 1589-97.
[http://dx.doi.org/10.1086/587109] [PMID: 18419495]
[35]
Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53(4): 480-4.
[http://dx.doi.org/10.1097/QAI.0b013e3181bc478b] [PMID: 19801944]
[36]
Msimanga PW, Vardas E, Engelbrecht S. HIV-1 diversity in an antiretroviral treatment naïve cohort from Bushbuckridge, Mpumalanga Province, South Africa. Virol J 2015; 12(1): 24.
[http://dx.doi.org/10.1186/s12985-015-0244-1] [PMID: 25889106]
[37]
Nwobegahay J, Selabe G, Ndjeka NO, Manhaeve C, Bessong PO. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa. J Med Virol 2012; 84(12): 1839-43.
[http://dx.doi.org/10.1002/jmv.23348] [PMID: 23080485]
[38]
Middelkoop K, Rademeyer C, Brown BB, et al. Epidemiology of HIV-1 subtypes among men who have sex with men in Cape Town, South Africa. J Acquir Immune Defic Syndr 2014; 65(4): 473-80.
[http://dx.doi.org/10.1097/QAI.0000000000000067] [PMID: 24583617]